TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tonix Pharmaceuticals Holding Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.73−0.31 (-5.13%)
Close on Oct 19, 2026
- Market cap
- $95.32M
- P/E (TTM)
- –
- Dividend yield
- –
Tonix Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $98.28M | $197.05M |
| Enterprise Value | -$77.96M | $106.56M |
| PS Ratio | 3.38 | 3.93 |
| PB Ratio | 0.44 | 2.14 |
| P/TBV Ratio | 0.44 | 2.46 |
Enterprise value
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | -2.68 | 2.69 |
Income (trailing twelve months)
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $29.10M | $57.94M |
| Gross Profit | $24.40M | $90.47M |
| Operating Income | -$165.43M | -$21.44M |
| Net Income | -$159.67M | -$22.46M |
| EBITDA | -$163.38M | -$16.91M |
| EPS (Diluted) | -$12.92 | -$0.83 |
Margins
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 83.8% | 52.3% |
| Operating Margin | -568.4% | -44.5% |
| Profit Margin | -548.6% | -39.2% |
| EBITDA Margin | -561.4% | -31.3% |
| FCF Margin | -543.3% | -8.85% |
Returns
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -81.8% | -53.1% |
| Return on Assets (ROA) | -72.3% | -41.0% |
| Return on Invested Capital (ROIC) | -297.6% | -32.0% |
| Return on Capital Employed (ROCE) | -74.1% | -37.8% |
Growth
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 196.0% | 6.01% |
Balance sheet
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $176.23M | $62.42M |
| Net Cash (Debt) | $176.23M | $15.68M |
| Net Cash Per Share | $10.28 | $0.65 |
| Equity (Book Value) | $222.28M | $48.79M |
| Book Value Per Share | $12.96 | $1.36 |
| Tangible Book Value | $222.16M | $23.06M |
| Working Capital | $172.65M | $75.77M |
Financial position
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 6.61 | 3.30 |
| Quick Ratio | 6.11 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$152.99M | -$12.35M |
| Capital Expenditures | -$5.12M | -$1.06M |
| Free Cash Flow | -$158.11M | -$20.28M |
| FCF Per Share | -$9.22 | -$0.41 |
Efficiency
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.38 |
| Revenue Per Employee | $204.94K | $398.96K |
| Profits Per Employee | -$1.12M | -$732.08K |
| Employee Count | 142 | 73 |
Dividends and yields
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -162.5% | -21.2% |
| FCF Yield | -160.9% | -7.64% |
| Buyback Yield | -219.2% | -0.58% |
| Shareholder Yield | -219.2% | 0.00% |
Shares
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 17,151,000 | 59,128,900 |
| Shares Change (QoQ) | 18.2% | 0.54% |
| Float | 17,109,100 | 48,744,500 |
| Shares Held by Insiders | 0.24% | 11.8% |
| Shares Held by Institutions | 54.6% | 59.4% |
Scores
| Measure | Tonix Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -4.52 | 0.10 |
| Piotroski F-Score | 6 | 4 |
| Beneish M-Score | -2.42 | -2.62 |
Calculated by StockData from Tonix Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.